Earnings call transcript: Braskem Q1 2026 beats EPS forecasts significantly By Investing.com

Braskem delivered a sharp Q1 2026 earnings beat, with EPS of $0.5059 versus a forecast loss of -$0.3937 and revenue of $3.15 billion, while recurring EBITDA rose 76% QoQ to $192 million. The stock was up 3.42% premarket to $4.98, but management emphasized ongoing liquidity pressure, high leverage at 16.81x EBITDA, and exposure to geopolitical disruptions that are lifting feedstock and resin spreads. The call also pointed to potential capital structure restructuring and continued focus on working capital preservation.

Analysis

BAK is trading like a duration-free option on geopolitical tightness, but the cleaner read is that the quarter proves operating leverage works in both directions: incremental spread expansion is now flowing through despite weak balance-sheet optics. The more important second-order effect is that management’s willingness to run the asset base harder is constrained less by demand than by feedstock access and working-capital financing, which means any further spread upside is likely to accrue disproportionately to companies with cleaner liquidity and better supplier terms, not necessarily the highest nominal capacity.

The market is probably underestimating how asymmetric the next 1-2 quarters could be. If feedstock disruption persists, BAK can show continued EBITDA step-up while cash burn worsens, forcing the stock to trade off a tug-of-war between near-term earnings momentum and refinancing risk. That creates a classic “good news is bad news” setup: stronger operations may actually tighten the pressure to address the capital structure sooner, especially with the standby facility and leverage metrics in the background.

The bigger contrarian point is that this is not a pure petrochemical beta trade; it is a liquidity event trade with embedded geopolitical optionality. Consensus may be overweighting the quarter’s EBITDA inflection and underweighting how quickly working capital can reverse that benefit if receivables stretch or inventory must be rebuilt into a volatile input market. On the other side, if management can secure even modest supplier financing and receivable monetization, the operating runway could extend long enough for the market to re-rate BAK from distressed to cyclical before any formal restructuring catalyst appears.

Key Decisions for Investors

• Long BAK vs short PBR for 4-8 weeks: BAK has more direct spread torque from petrochemical tightness, while PBR’s upside is more diluted by upstream/downstream offset; use a 1:1 notional pair and take profit if BAK outperforms by 15-20%.
• Buy BAK call spreads, 1-2 months out, struck around current trading levels: thesis is a fast EBITDA re-rate on continued supply disruption, but cap the premium because liquidity/refinancing risk can dominate on any headline reversal.
• Short BAK common against long XOP or a stronger balance-sheet chemical proxy if the stock spikes on geopolitical headlines: this is a sell-the-pop name because the financing overhang can reassert within days if working-capital stress worsens.
• Watch BTG/XP sentiment as a catalyst filter rather than a trade: if local brokers start upgrading BAK on EBITDA momentum alone, fade the move unless there is simultaneous evidence of improved cash conversion and supplier terms.